One of the major highlights of the 2021's guideline update was that sodium-glucose cotransporter-2 (SGLT-2) inhibitors or glucagon-like peptide 1 (GLP-1) agonists (if SLGT-2 is not well tolerated) be used in people with diabetes with comorbid conditions such as chronic kidney disease and heart failure, irrespective of HbA1C or metformin use. This evidence concerns the gene GCG and chronic kidney disease.